From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases

Author:

Pavord Ian D.1ORCID,Bel Elisabeth H.2,Bourdin Arnaud34ORCID,Chan Robert5,Han Joseph K.6,Keene Oliver N.7,Liu Mark C.8,Martin Neil910,Papi Alberto11ORCID,Roufosse Florence12,Steinfeld Jonathan13,Wechsler Michael E.14,Yancey Steven W.15

Affiliation:

1. Nuffield Department of Medicine and Oxford Respiratory NIHR BRC University of Oxford Oxford UK

2. Department of Respiratory Medicine Amsterdam UMC University of Amsterdam Amsterdam The Netherlands

3. INSERM 12 F‐CRIN Clinical Research Initiative In Severe Asthma: a Lever for Innovation & Science (CRISALIS) France

4. Service de Pneumologie and INSERM CNRS CHU Montpellier Université de Montpellier Montpellier France

5. Clinical Sciences GSK R&D Stockley Park UK

6. Department of Otolaryngology, Head & Neck Surgery Eastern Virginia Medical School Norfolk Virginia USA

7. Biostatistics GSK Brentford UK

8. Divisions of Allergy and Clinical Immunology, Pulmonary and Critical Care Medicine Johns Hopkins Asthma and Allergy Center Baltimore MD USA

9. Global Medical Affairs GSK Brentford UK

10. Institute for Lung Health University of Leicester Leicester UK

11. Research Center on Asthma and COPD University of Ferrara Ferrara Italy

12. Department of Internal Medicine Hôpital Erasme Université Libre de Bruxelles Brussels Belgium

13. Respiratory Research & Development GSK Collegeville PA USA

14. Department of Medicine National Jewish Health Cohen Family Asthma Institute Denver CO USA

15. Respiratory Therapeutic Area Unit GSK Research Triangle Park NC USA

Funder

GlaxoSmithKline

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Reference152 articles.

1. Targeting eosinophils in allergy, inflammation and beyond

2. Eosinophils and Disease Pathogenesis

3. Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

4. GSK.Mepolizumab US prescribing information. Updated 2020.https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA‐PI‐PIL‐IFU‐COMBINED.PDF. Accessed October 07 2020.

5. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in mild asthmatics

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3